Literature DB >> 24274442

Oncological outcomes after endoscopic removal of malignant colorectal polyps.

Bruno Moreira Gonçalves, Vasco Fontainhas, Ana Célia Caetano, Aníbal Ferreira, Raquel Gonçalves, Pedro Bastos, Carla Rolanda.   

Abstract

OBJECTIVE: malignant colorectal polyp, defined by submucosally invasive adenocarcinoma, is the earliest form of clinically relevant colorectal cancer (CRC). After endoscopic resection additional surgery may be necessary, although decision criteria remain debatable. The objective of this study was to assess oncologic outcomes in terms of locoregional disease and to identify areas of improvement that may facilitate patients' management.
METHODS: retrospective study of 40 patients with T1 CRC endoscopically resected between 2007 and 2012. Clinicopathological features were assessed and correlated with residual disease (RD), defined as presence of adenocarcinoma in intestinal wall and/ or lymph nodes.
RESULTS: thirty-one patients underwent surgery while 9 were followed-up. After surgery, RD was confirmed in 15 (48.4%) patients: 8 (53.3%) wall disease, 5 (33%) nodal metastasis, and 2 (13.3%) with both. No recurrence was detected in the follow-up group. The characteristics of the lesions that were associated with DR were sessile configuration (p = 0.03), the degree of differentiation G3 (p = 0.01) and intercepted/indeterminate margins (p = 0.01). Twenty-two patients were operated because of inadequate evaluation, mainly due to piecemeal resection, and half of them were disease free. Postoperative complications were found in 9 (30%) patients, mainly anastomotic leakage that was associated with rectum anterior resection (p = 0.03).
CONCLUSIONS: surgery should be considered in the presence of any risk factor for residual disease, while follow-up can be offered in low risk settings. Was also demonstrated a clear need for technical improvement in endoscopic resection and pathology evaluation in order to prevent unnecessary surgeries.

Entities:  

Mesh:

Year:  2013        PMID: 24274442     DOI: 10.4321/s1130-01082013000800003

Source DB:  PubMed          Journal:  Rev Esp Enferm Dig        ISSN: 1130-0108            Impact factor:   2.086


  5 in total

1.  British Society of Gastroenterology/Association of Coloproctologists of Great Britain and Ireland guidelines for the management of large non-pedunculated colorectal polyps.

Authors:  Matthew D Rutter; Amit Chattree; Jamie A Barbour; Siwan Thomas-Gibson; Pradeep Bhandari; Brian P Saunders; Andrew M Veitch; John Anderson; Bjorn J Rembacken; Maurice B Loughrey; Rupert Pullan; William V Garrett; Gethin Lewis; Sunil Dolwani
Journal:  Gut       Date:  2015-06-23       Impact factor: 23.059

2.  Factors predicting occurrence and therapeutic choice in malignant colorectal polyps: a study of 13 years of colonoscopic polypectomy.

Authors:  Sergiu Marian Cazacu; Adrian Săftoiu; Sevastiţa Iordache; Mirela Corina Ghiluşi; Claudia Valentina Georgescu; Vlad Florin Iovănescu; Carmen Daniela Neagoe; Liliana Streba; Mihaela Caliţa; Elena Daniela Burtea; Dan Cârţu; Polliana Mihaela Leru
Journal:  Rom J Morphol Embryol       Date:  2021 Oct-Dec       Impact factor: 0.833

3.  Increased Rate of Incidental Colorectal Malignant Polyps: A Single-Center Experience.

Authors:  T Buchbjerg; R Kroijer; I Al-Najami; K Urth Hansen; G Baatrup
Journal:  Surg Res Pract       Date:  2018-04-23

4.  Patient and pathological predictors of management strategy for malignant polyps following polypectomy: a systematic review and meta-analysis.

Authors:  Andrew P Zammit; Nicholas J Lyons; Mark D Chatfield; John D Hooper; Ian Brown; David A Clark; Andrew D Riddell
Journal:  Int J Colorectal Dis       Date:  2022-04-08       Impact factor: 2.796

5.  Predictive microRNAs for lymph node metastasis in endoscopically resectable submucosal colorectal cancer.

Authors:  Chan Kwon Jung; Seung-Hyun Jung; Seon-Hee Yim; Ji-Han Jung; Hyun Joo Choi; Won-Kyung Kang; Sung-Won Park; Seong-Taek Oh; Jun-Gi Kim; Sug Hyung Lee; Yeun-Jun Chung
Journal:  Oncotarget       Date:  2016-05-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.